You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK):2022營收逆勢激增91.1%至32億元 期內達成多項海外授權 凸顯強大的商業化實力
格隆匯 03-31 23:33

2023年3月31日,復宏漢霖(2696.HK)發佈2022年度業績,於業績期內實現營業收入約人民幣32.147億元,較去年同期增長約91.1%,主要來自商業化產品高速增長的銷售收入及海外授權許可收入等。截至目前,復宏漢霖已有5款產品在中國上市,1款產品在全球上市,18項適應症獲批,加速拓展全球商業化版圖。同時,公司持續加碼差異化創新,推動多元化創新管線進入新階段,2022年度研發投入約人民幣21.832億元。

復宏漢霖董事長、執行董事兼首席執行官張文傑先生表示:"2022年是復宏漢霖極具里程碑意義的一年,我們在難中攀高,在穩中求進,高質量完成向Biopharma進化。其中,我們的業績在疫情下逆勢增長,營收突破30億人民幣,已上市的5款產品實現了銷售快速放量,再次凸顯了強大的商業化實力。此外,公司商務合作領跑全國,多款上市和在研產品達成海外授權,首付款總額逾人民幣15億。在公司自研生物類似藥和創新藥的雙驅動下,復宏漢霖正邁向更高層次的發展,並將持續提升市場競爭力,以期打造中國生物製藥領導者形象,攜手社會各方實現共同超越!

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account